Santen Pharmaceutical , Ltd. posts a ROE of 13.03%. That is above the sector sector average of 11.75%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near 11.75% is typical. Santen Pharmaceutical , Ltd.'s 13.03% is higher that level. That is roughly 10.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Santen Pharmaceutical , Ltd.'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 13.03%; use YoY and peer views to separate noise from signal.

Context for SNPHF's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.75%), and (3) consistency with growth and profitability. This page covers the first two; Santen Pharmaceutical , Ltd.'s other metric pages and overview cover the third.